← Back to Search

Hormone Therapy

Testosterone enanthate auto-injector for Low Testosterone

Phase 3
Waitlist Available
Led By Gary Bedel, MD
Research Sponsored by Antares Pharma Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 26 weeks
Awards & highlights

Summary

Evaluation of safety of a concentration controlled testosterone enanthate QuickShot Testosterone regimen administered subcutaneously once each week to adult males with hypogonadism.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~26 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 26 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Adverse Events as a Measure of Safety of QuickShot™ Testosterone (QST) Administered Subcutaneously (SC) Once Each Week to Adult Males With Hypogonadism

Side effects data

From 2015 Phase 3 trial • 150 Patients • NCT02159469
14%
Hematocrit increased
13%
Hypertension
12%
Prostatic specific antigen increased
8%
Upper respiratory tract infection
7%
Sinusitis
7%
Injection site bruising
5%
Headache
4%
Nasopharyngitis
3%
Bronchitis
3%
Edema peripheral
3%
Injection site hemorrhage
3%
Injection site erythema
3%
Back pain
3%
Blood creatine phosphokinase increased
3%
Blood testosterone increased
3%
Influenza
3%
Urinary tract infection
3%
Acne
3%
Prostatitis
3%
Cough
2%
Eczema
2%
Fatigue
2%
Sinus congestion
2%
Polycythemia
2%
Hemorrhoids
2%
Hematuria
2%
Sleep apnea syndrome
2%
Abdominal pain
2%
Arthralgia
1%
Vertigo
1%
Suicide
1%
Depression
100%
80%
60%
40%
20%
0%
Study treatment Arm
Testosterone Enanthate Auto-injector

Trial Design

1Treatment groups
Experimental Treatment
Group I: Testosterone enanthate auto-injectorExperimental Treatment1 Intervention
Testosterone enanthate 50 mg / 75 mg / 100 mg administered subcutaneously once each week with possible titration to a higher or lower dose at scheduled intervals during study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Testosterone enanthate
FDA approved

Find a Location

Who is running the clinical trial?

Antares Pharma Inc.Lead Sponsor
10 Previous Clinical Trials
1,101 Total Patients Enrolled
Gary Bedel, MDPrincipal InvestigatorPrestige Clinical Research
1 Previous Clinical Trials
39 Total Patients Enrolled
~13 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top